Jackisch, C., Hegg, R., Stroyakovskiy, D., Ahn, J., Melichar, B., Chen, S., . . . Pivot, X. (2016). HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Citación estilo ChicagoJackisch, Christian, et al. HannaH Phase III Randomised Study: Association of Total Pathological Complete Response With Event-free Survival in HER2-positive Early Breast Cancer Treated With Neoadjuvant-adjuvant Trastuzumab After 2 Years of Treatment-free Follow-up. 2016.
Cita MLAJackisch, Christian, et al. HannaH Phase III Randomised Study: Association of Total Pathological Complete Response With Event-free Survival in HER2-positive Early Breast Cancer Treated With Neoadjuvant-adjuvant Trastuzumab After 2 Years of Treatment-free Follow-up. 2016.
